Mobile website
Prompt Report
Preliminary analysis of clinical efficacy of cytokine-induced killer cells in treatment of patients with melanoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the efficacy of cytokine-induced killer cells (CIKs) in the treatment of melanoma．Methods: Thirty-eight post-operated melanoma patients in Tumor Hospital Affiliated to Tianjin Medical University from January 2005 to December 2010 receiving CIK treatment were obtained (CIK group) as a treatment group, and 114 melanoma patients without treatment were obtained as a control group. Pairing considerations included clinical stage, gender, age, ulceration, lactate dehydrogenase （LDH） activity, pathological type, and the Karnofsky performance status scale (KPS). The follow-up period was from March 2005 to March 2012. The endpoint of clinical efficacy was overall survival (OS)．Results: The 1-, 3-, 5-year OS rates in the CIK and control groups were 86.8% vs 74.6% (P=0.097), 76.3% vs 46.5% (P=0.001) and 71.1% vs 43.9% (P=0.004), respectively. The median OS in the CIK group was significantly longer than that in the control group (the OS in CIK group did not reach median OS, and was 20.1 months in the control group, P=0.004). The frequency of CIK immunotherapy may be related to the OS of melanoma patients (P=0051). It seemed a trend to prolong the OS of patients with melanoma when CIK treatment >8 times. Univariate and multivariate analysis showed that the pathological type and LDH activity were independent factors for the clinical efficacy of CIK in treatment of patients with melanoma. Conclusion: CIK immunotherapy can prolong OS in melanoma patients, and increasing CIK frequency may enhance the clinical efficacy.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 30901376), and the Public Special Foundation from the Ministry of Health of China (No. 200902002-2)
Clc Number:
